Assertio Holdings, Inc. (ASRT)

2,6400 +0,0100 (+0,38%) Al cierre: 04:00PM EDT

Assertio Holdings, Inc.

100 South Saunders Road
Suite 300
Lake Forest, IL 60045
United States
224 419 7106
https://www.assertiotx.com

Sector(es): Healthcare
Sector: Drug Manufacturers—Specialty & Generic
Empleados a tiempo completo: 30

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Daniel A. Peisert	Pres, CEO & Director	2,18M	N/A	1975
Mr. Paul Schwichtenberg	Sr. VP & CFO	780,88k	N/A	1971
Mr. Ajay Patel	Sr. VP & Chief Accounting Officer	742,01k	N/A	1984
Mr. Bill Iskos	Sr. VP of Operations	N/A	N/A	N/A
Mr. Sam Schlessinger	Sr. VP & Gen. Counsel	N/A	N/A	N/A
Mr. Jeff Christensen	Sr. VP of Commercial	N/A	N/A	N/A
Dr. Howard J. Franklin M.B.A., M.D.	Sr. VP of Medical	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Gobierno corporativo

El ISS Governance QualityScore de Assertio Holdings, Inc., a día 1 de septiembre de 2023, es 1. Las puntuaciones base son Auditoría: 6; Tablero: 3; Derechos de los accionistas: 1; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.